The delivery of infants before 37 weeks gestation is a leading cause of perinatal mortality and morbidity in the United States. Traditional methods of predicting women at risk relying on obstetric history or premonitory symptoms (detected clinically or by tocodynamometry) are neither sensitive nor specific. Recent approaches to predicting preterm delivery have included sonographic measurement of cervical length and various biochemical assays. Although more sensitive than traditional methods, none of these alone exhibits sufficient accuracy to warrant widespread use. We contend that the failure of current approaches to predicting preterm delivery reflects an inadequate understanding of the underlying pathogenesis. Clinical and experimental evidence support the concept that most cases of preterm delivery reflect four pathogenic processes, which share a common final biological pathway leading to uterine contractions and cervical changes with or without premature rupture of membranes. These pathogeneses are: (1) activation of the maternal or fetal hypothalamic-pituitary-adrenal axis; (2) decidual-chorioamniotic or systemic inflammation; (3) decidual haemorrhage (i.e. abruption); and (4) pathological distention of the uterus. Our research seeks to combine the most useful biophysical and biochemical markers of such processes with optimal clinical and epidemiological predictors into a composite, easily applied risk tool. This integrated approach has the potential to identify at-risk asymptomatic patients with high sensitivity, specificity, and positive and negative predictive values, and also to ascertain underlying pathogenic processes that can lead to targeted therapy. To accomplish these goals, we employ logistic regression and artificial neural network models to assess and apply the appropriate weight to markers associated with each of the above pathogenic pathways, in addition to markers of the final common pathway leading to fetal membrane rupture, cervical extracellular matrix degradation, and myometrial activation.
Summary
The delivery of infants before 37 weeks gestation is a leading cause of perinatal mortality and morbidity in the United States. Traditional methods of predicting women at risk relying on obstetric history or premonitory symptoms (detected clinically or by tocodynamometry) are neither sensitive nor specific. Recent approaches to predicting preterm delivery have included sonographic measurement of cervical length and various biochemical assays. Although more sensitive than traditional methods, none of these alone exhibits sufficient accuracy to warrant widespread use. We contend that the failure of current approaches to predicting preterm delivery reflects an inadequate understanding of the underlying pathogenesis. Clinical and experimental evidence support the concept that most cases of preterm delivery reflect four pathogenic processes, which share a common final biological pathway leading to uterine contractions and cervical changes with or without premature rupture of membranes. These pathogeneses are: (1) activation of the maternal or fetal hypothalamic-pituitary-adrenal axis; (2) decidual-chorioamniotic or systemic inflammation; (3) decidual haemorrhage (i.e. abruption); and (4) pathological distention of the uterus. Our research seeks to combine the most useful biophysical and biochemical markers of such processes with optimal clinical and epidemiological predictors into a composite, easily applied risk tool. This integrated approach has the potential to identify at-risk asymptomatic patients with high sensitivity, specificity, and positive and negative predictive values, and also to ascertain underlying pathogenic processes that can lead to targeted therapy. To accomplish these goals, we employ logistic regression and artificial neural network models to assess and apply the appropriate weight to markers associated with each of the above pathogenic pathways, in addition to markers of the final common pathway leading to fetal membrane rupture, cervical extracellular matrix degradation, and myometrial activation.
By combining these markers, we expect ultimately to produce a predictive model that is more robust than any existing method, and that identifies the relative contribution of each pathogenic process. Further analysis of this model using a neural network will enable us to identify asymptomatic patients destined to deliver preterm with high sensitivity, specificity, positive and negative predictive values, and to assess the relative contribution of each of the four distinct pathogeneses to this preterm delivery risk. Traditional methods for predicting women destined to deliver preterm relied on obstetric history, demographic factors, or premonitory symptoms that were neither sensitive nor specific. 4, 5 Clinical markers used commonly include cervical change, increasing contraction frequency and vaginal bleeding. The relative inefficiency of these approaches has been reviewed extensively. 6, 7 PTD risk-scoring systems based on arbitrarily selected epidemiological, historical and clinical risk factors have also proved to be insensitive and non-specific. 7±10 Similarly, sensitive ambulatory tocodynamometry, employed to enhance the early detection of asymptomatic uterine contractions, has not been shown to reduce PTD rates, despite an increase in the number of patients eligible for tocolysis. 11, 12 We contend that the failure of traditional approaches to the prediction of patients at risk for PTD stems from an inadequate understanding of its underlying pathogenesis. Clinical and experimental evidence supports the concept that most cases of PTD reflect four major pathogenic processes, which share a common final biological pathway leading to uterine contractions and cervical changes with or without premature rupture of membranes. These PTD pathogeneses are: (1) activation of the maternal or fetal hypothalamic-pituitaryadrenal (HPA) axis; (2) decidual-chorioamniotic or systemic inflammation; (3) decidual haemorrhage (abruption); and (4) pathological distention of the uterus. Though they often occur simultaneously, each of these four processes manifests a distinct epidemiological profile as well as unique biochemical and biophysical pathways initiating parturition. Ultimately, they each converge on a final common biochemical pathway involving myometrial activation and stimulation and enhanced genital tract protease activity promoting PPROM and cervical change. This pathway is characterised by cervical and fetal membrane extracellular matrix degradation and myometrial activation leading to cervical dilation, membrane rupture and uterine contractions These pathways are summarised in Fig. 1 . Recent approaches to predicting PTD, including sonographic measurement of cervical length and biochemical assays for human chorionic gonadotropin (hCG), cytokines, fetal fibronectin (fFN), matrix metalloproteinases (MMPs), oestrogens, and corticotropinreleasing hormone (CRH), although more sensitive than traditional methods, do not achieve sufficient reliability to warrant their use in all patients. While many of these markers play a role on at least one of the purported pathways, a single assessment of only one of them at a single point in time does not provide a definitive PTD risk assessment. It is clear, given the heterogeneous, interactive aetiopathogeneses of PTD, that single biochemical markers and pooled epidemiological risk factors are doomed to failure, as they will lack sufficient sensitivity and specificity, and fail to detect the contribution of each pathogenesis. 13 Current statistical techniques cannot easily integrate multiple, interactive epidemiological, clinical, biochemical, and biophysical variables, and thus are inadequate to meet the challenge of predicting patients at risk for PTD or identifying underlying pathogeneses to permit targeted therapy. Such a complex model requires the use of an artificial neural network.
Methods

Overview
The research design described here represents a longterm, prospective, observational study of a cohort of pregnant women with a PTD rate of approximately 10%, which mimics the overall PTD rate in the US. We are recruiting patients at their first antenatal visit and following them until delivery. Demographic, psychological, and social information is gathered by means of a formal questionnaire and by interviewing the patients at recruitment and at each prenatal visit until 32 weeks' gestation. Clinical information and biological specimens are collected during routine prenatal visits. Primary endpoints are the timing of PTD from either spontaneous rupture of membranes or spontaneous onset of labour. Secondary endpoints include the diagnosis of placental abruption, chorioamnionitis, uteroplacental vascular abnormality, and pathological distension (see Table 1 for criteria for these endpoints). We will ultimately analyse the biological specimens and epidemiological data selectively in the form of a 1:2 nested case-control study. This analytical approach has been selected because of its powerful yet economical design features. There is no intervention; rather, enrolled women are followed until the primary outcome (delivery). Retrospectively, women who deliver preterm are grouped into the`case' category, whereas those who deliver at term represent the control population. From this latter group of term deliveries, a subset is matched, in this case using a two-to-one ratio, with cases on the basis of age, parity, ethnicity, and gestational age of biological specimen sampling. In this manner, many fewer control samples need to be processed in order to maintain the same statistical power to detect differences between groups. As our control group consists of several thousand women C. J. Lockwood Figure 1 . Pathways of preterm delivery resulting from preterm premature rupture of the membranes and/or preterm labour. with multiple biological specimens sampled at different gestational ages, substantial time and cost savings accrue through selective use of control specimens.
As of this writing, the primary predictor (`independent') variables that we have identified are, for HPA axis activation: levels of CRH, insulin-like growth factor binding protein 1 (IGFBP-1), estriol (E3), hCG, and uterine artery Doppler resistance index, pulsatility index, and notching; for inflammation: cervicovaginal and serum levels of interleukin 6 and 8 (IL-6, IL-8), colony stimulating factor (CSF), and soluble Fas ligand (FasL), as well as presence of bacterial vaginosis (BV); for haemorrhage: occult vaginal blood, thrombinantithrombin-III (TAT) complexes, and plasma tissue factor; and for pathological uterine distention: fetal number, amniotic fluid index, and history of diethylstilboestrol exposure or uterine anomalies. Final common pathway predictors are levels of fFN, MMP-1, and MMP-9, and sonographic determination of cervical length.
Inclusion criteria
Upon enrolment, the patient must be less than 18 weeks' gestation, must understand and sign an Institutional Board of Research Associates approved consent form, and have a well-confirmed estimated date of confinement from last menstral period or ultrasound (see 18 ).
Exclusion criteria
Patients ineligible to enrol or who will be subsequently excluded are those with elective termination of pregnancy, intrauterine fetal death before 24 weeks' gestation, or first prenatal visit after 18 weeks' gestation. Medically indicated PTDs resulting from one of the clinical endpoints are not excluded.
Data collection
Each patient is seen following her routine prenatal care visit between 17 and 28 weeks' gestation. Participants complete a detailed risk assessment questionnaire, are interviewed in conjunction with this instrument, have cervical length evaluated by cervical sonography, and provide cervicovaginal secretions and a blood sample for future analysis. At the initial visit each woman receives a questionnaire concerning her sociodemographic, obstetric and gynaecological history, environmental exposure, nutrition, and anthropometric background. Between 20 and 22 weeks' gestation, uterine artery Doppler flow studies are conducted during the course of a standard Level II ultrasound anatomy examination.
Sociodemographic, psychosocial and obstetric history measures
We designed and tested the self-completed questionnaire administered during the first study visit. A trained interviewer collects this from the patient, reviews it, and discusses any missing or suspect responses with the patient. The survey instrument has benefited from prior sociodemographic surveys of risk developed by Berkowitz, 2±19 and has been extensively modified and tested. It includes assessment of individual indicators of socio-economic status (maternal and paternal education, occupation and family income), environmental stress-related factors, levels of physical activity, dietary factors, psychosocial characteristics (life-change events, attitudinal expression toward the pregnancy), tobacco and substance use, genital hygiene including the use of douching, and sexual behaviour of both the woman and her partner(s).
In an effort to use scales that are standardised and reproducible, we attempted to incorporate published methods whenever possible. Occupational, educational, and income categories reflect the United States Bureau of the Census classification schemata, 20 while our life-change events list is based on the social readjustment rating scale. 21 We avoided construction of a composite socio-economic status score, as recent thinking in the field argues against the scientific value of composite indexes of occupational socio-economic status. 22 We do, however, construct single composite subjective stress and exercise scores from the survey. As all participants receive routine prenatal care at one of the participating clinics, obstetric history and other relevant demographic data are extracted from the medical chart. We collect maternal anthropometric and constitutional variables in this fashion.
Assessment for bacterial vaginosis (BV) and occult blood
Two cotton swabs are inserted into the posterior vaginal fornix and saturated with vaginal secretions. Sample pH is measured with pH test strips from Sigma Chemical Co. One swab is then treated with 10% potassium hydroxide, and observed for the characteristic amine odour associated with BV. Another swab is used for a wet mount slide, which is examined under a microscope. The presence of`clue cells' (squamous epithelial cells heavily stippled with bacteria), together with a paucity of lactobacillus, a pH 4 4.5, and a positive KOH test confirm the diagnosis of BV. In the absence of gross evidence of vaginal bleeding, a third swab is used to rule out occult blood using the Seracult test (Propper Manufacturing Co., Inc., Long Island City, NY).
Blood sampling
Blood samples are collected for assessment in serum of the relevant markers ( Table 2) . Following informed consent, serum (6 mL) and EDTA plasma (6 mL) samples are obtained during prenatal visits at approximately 17, 22, 25, and 28 weeks. The samples are stored on ice until centrifugation within two hours at 5000 r.p.m. for 10 min at a satellite laboratory in our department at Bellevue Hospital. Each blood collection specimen is divided into a minimum of six 1 mL aliquots of serum and plasma, yielding a sufficient specimen volume for duplicate assays without repeated freeze-thawing of samples. The buffy coat of the EDTA samples is extracted and stored for DNA analysis. A protease inhibitor cocktail 23 is added to one aliquot of serum and plasma to preclude protease degradation. Aliquots of each serum or plasma sample are labelled and stored at 7708C until assayed in the department's laboratories. The preparation procedure is designed to maximise the potential number of assays that can be performed, and to allow for the flexibility to investigate promising new markers that may be found in the future.
Cervicovaginal sampling
Cervicovaginal secretions are obtained via sterile speculum examination of the vagina. Two Dacron swabs are introduced into the posterior fornix of the vagina and left in place for 30 s. The swabs are rotated a minimum of six times during this time. Using identical technique, third and fourth swabs are is placed intracervically to obtain cervical secretions. One each of the vaginal and cervical swabs are then placed in 750 mL of Tris buffered saline, pH 7.4, containing 2 mg/mL bovine serum albumin. The other two are placed in the same buffer, plus a protease inhibitor cocktail. 23 Samples are aliquotted and stored at 7708C for subsequent analysis of fFN, FasL, CSF, IL-6, IL-8, MMP-1, and MMP-9. Assays for fFN, IL-6, and IL-8 are run in the department's immunoassay laboratory. These proteins can be detected by commercially available enzyme-linked immunosorbent assay (ELISA). following Dacron swab sample acquisition. Measurements are taken when the uterus is not contracting. Our protocol is modified from Iams et al. 24 The examination, which lasts approximately 3 min, follows a stepwise protocol of identifying the internal cervical os, the cervical canal, and the external os, and then relaxing pressure on the transducer to the point at which the image becomes blurred. Gentle pressure sufficient to recreate a good cervical image is then reapplied. This method minimises the problem of excessive transducer pressure leading to overestimation of cervical length. This phenomenon is familiar to experienced cervical ultrasonographers and does not disappear with increasing experience. The distance between the`notches' made by the junction of the anterior and posterior cervical walls at the internal and external os is recorded in millimetres. The cervix is measured three times, and the shortest optimal image is used. 24 The examinations are performed by sonographers who have been fully trained in the technique by seasoned perinatologists who are recognised experts in cervical ultrasound assessment. To minimise interobserver variability, we require that more than 75% of the examinations at each site are performed by the same individual.
Cervical length assessments
Ultrasound assessments
Gestational age is optimally assessed via a crownrump length measurement (in mm) between 6 and 12 weeks' gestation, which is considered to be accurate with a standard error of + 1 week. Gestational age assessment in the second trimester (i.e. after 12 weeks) is best performed using a combination of biparietal diameter, head circumference, abdominal circumference, and femur length. We incorporate these measurements into the standard equation developed by Hadlock et al. 25 between 12 and 20 weeks. The standard error is + 2 weeks. Gestational age determination is more accurate at earlier ages, so we estimate it sonographically at the initial visit. Between 20 and 22 weeks gestational age, each woman receives a comprehensive ultrasound evaluation in one of our obstetric ultrasound units using either an Acuson XP 128-OB (Acuson, Mountain View, CA) or an ATL 5000 (ATL, Bothell, WA). During this examination, we obtain definitive data on fetal number, amniotic fluid index, estimated fetal weight percentile, and uterine artery Doppler flows, the last of these according to the protocol described by Schulman et al. 26 Confirmation of vessel pattern is obtained by duplex imaging. Abdominal studies are done by directing the transducer into the parauterine area in the region of the lower uterine segment. The probe is gently rotated until the appropriate pattern is identified. Examinations are carried out in the left or right tilt position. Wave forms are acceptable for measurement when they are dense and of equal amplitude, and an effort is made to obtain the largest complexes possible. The ultrasound machine computes the resistance index and the pulsatility index of the artery, while the presence of notching is noted. Evaluation of the uterus to assess possible exposure to diethylstilboestrol and presence of Mu È llerian anomalies is conducted during this examination. A second scan is performed at 28 weeks' gestation for repeat measurement of estimated fetal weight and amniotic fluid index. non-phosphorylated IGFBP-1 are measured using a second ELISA also available through Diagnostic Service Laboratories. Quantitation of FasL requires that we prepare our own`sandwich immunoassay' by coating 96-well microtitre plates with mouse anti-human FasL antibody obtained from Transduction Laboratories (Lexington, KY) which recognises the extracellular domain of FasL. After addition of samples, a second anti-FasL Risk stratification and pathological mechanismsantibody that recognises the intracellular portion of FasL (Santa Cruz Biochemical, Santa Cruz, CA) is added. Colour development and quantitation are carried out. 28 Results from the FasL ELISA are corroborated using Western blotting. 29 Levels of CRH in sera will be measured by radioimmunoassay (RIA). 30 Briefly, as only free CRH (i.e.
Biochemical measurement of PTD markers
that fraction not bound to CRH binding protein) is biologically active, free CRH will be measured following selective binding and elution using a Sep Pak Plus C18 column. In this RIA a standard curve is constructed using a constant concentration of 125 I-CRH that competes with unlabelled CRH (between 1 and 100 fmol/assay tube) for binding to rabbit anti-CRH antiserum. The antibody-CRH complex is precipitated using donkey anti-rabbit secondary antibody conjugated to magnetic beads. For confirmatory assay, 10% of the samples will be sent to the laboratory of Dr Felice Petraglia (Udine, Italy), who has extensive experience in the measurement of CRH and CRHbinding protein.
31,32
Biological specimen bank Serum, cervicovaginal, and DNA samples of all cases and controls are coded, entered into a tracking database, and stored in research freezers at a minimum of 7708C. The freezers are equipped with emergency liquid CO 2 backup systems and an alarm system connected to an automatic telephone paging system, which notifies up to five different programmed telephone numbers repeatedly, until it receives confirmation, in the event of a power or compressor failure.
Data management
Data from the prenatal charts are abstracted onto a clinical information sheet. The project assistant enters this sheet and the questionnaire into a relational database (Oracle, Oracle Corporation, Redwood Shores, CA) through a series of existing entry screens custom designed for this purpose. The screens contain a host of validity and range checks to minimise the possibility of data entry error. In addition, journal entry reports list the details of each record entered or updated, and these reports are compared with the source documents. The database is stored on a School of Medicine minicomputer, with a daily backup copy created on the departmental file server, which is located in a different building on campus. This file server has its contents archived to tape once weekly as part of medical centre routine backup processes.
For statistical analysis purposes, the database is exported to ASCII files, which are subsequently imported into the SAS statistical software package (SAS Institute, Cary, NC), and the NevProp artificial neural network program (University of Nevada School of Medicine, Reno, NV).
Sample size and power estimates
Based on prior studies and preliminary data, we estimate a PTD primary pathogenic pathway distribution of 40% caused by inflammation; 30% by HPA axis activation; 20% by bleeding; and 10% by uterine distention. We anticipate having to screen approximately 2800 patients to produce sufficient cases of PTD to detect meaningful differences between term and preterm deliveries. Sample size estimates were computed assuming a traditional statistical approach to a case-control analysis, based upon a minimum clinically meaningful effect size, which we established a priori at a relative risk of 2.0 or greater. To detect a relative risk of 2 between the 4th and 1st quantile groups of the relevant biomarkers with a two-sided 5% type I error, the smallest of the three case groups for which we can achieve sufficient power, bleeding-induced cases, requires 60 cases and 60 controls to achieve a minimum power of 80%. In 1999 approximately 2600 women received prenatal care at our two sites. Estimating participation at 50% (in our current study it is 54%), we can expect to accrue 247 PTD cases 24 months into the study (2600 patients 6 50% participation 6 9.5% PTD rate 6 2 years).
Thus, a minimum of a two-year period of recruiting is required to obtain sufficient bleeding-induced cases. We expect to obtain a total of 128 cases caused by infection and 96 cases caused by stress by the end of the two years, which will provide at least a 90% power for each of these two pathogenic pathwayspecific case-control studies, using the 60 controls of the bleeding-induced cases. We will not have sufficient power for PTD caused by pathological uterine distention during the initial case-control study. However, this pathogenic mechanism is relatively straightforward, has been well studied, and accounts for the smallest proportion of PTDs. As we plan to continue the cohort study indefinitely, we will return to this pathway when we have accrued sufficient additional cases.
Artificial neural network statistical method
The concept that learning can be viewed as the modification of information by repeatedly passing it through processing nodes, originated in the late 1940s as a way to model the physiology of neuronal processes. 33 The operationalisation of this idea was called an artificial neural network. Gradually it became apparent that this information theoretical approach to learning was very powerful and very general; it was useful in, and applicable to, many learning situations. Artificial neural networks are universal approximators. It has been shown that any real, continuous function can be approximated to any degree of precision by a three-layer network with x in the input layer (patient variables), a hidden layer of signmodal units, and one layer of output units (the outcome that is to be predicted, for example, PTD), as long as the hidden layer can be arbitrarily large. 34, 35 Artificial neural networks, as a class of non-linear regression and discrimination statistical methods, are of proven value in many areas of medicine.
36±42 They do not require a priori information regarding the phenomenon, they make no distributional assumptions and, with the appropriate method to avoid overfitting (i.e. loss of generalisation by fitting the patterns to the test data too precisely), artificial neural networks are usually at least as accurate as classical statistical models. For complex phenomena, they can be much more accurate. Artificial neural networks have, for example, been shown to be more accurate than logistic regression, CART (pruned or shrunk), and principal components analysis at predicting fiveyear breast cancer specific survival. 43 Preliminary data from current Bellevue Hospital Cohort Study
In order to collect preliminary data, a pilot cohort study was initiated at the Bellevue Hospital Center Women's Health Clinics in September 1996. We enrolled 619 women into the study up to February 1998, for an eligible patient participation rate of 54%. Demographic details of the participating population reflect those of the total clinic population. Study participants match the overall clinic population in age, parity, and PTD rate. For this study, we developed a risk assessment survey, which is currently administered in English or Spanish. For those patients who are literate in neither of these languages, we have been able to provide native language support from the hospital's interpreter pool.
MMP-1 in cervicovaginal secretions
Our data suggest that cervicovaginal MMP-1 levels are elevated significantly in patients delivering preterm vs. term. 44 In samples taken between 24 and 28 weeks' gestation, MMP-1 values were significantly higher in women who ultimately delivered preterm compared with those delivering at term (2.57 + 0.85 vs. 1.62 + 0.85 ng/mL, P = 0.05).
Cervical length, stress, and race
We have found a significant correlation between the length of the cervix and subjectively experienced stress among a group of women who experienced term deliveries. 45 Based on a number of responses, we derived a composite stress scale. Women scoring in the highest quartile of this scale developed shorter cervices than those with lower scores. These correlations suggest that we will find differences in early biochemical markers of stress in women who will deliver at term vs. preterm. In addition, we have found that black women developed shorter cervices than women of other ethnic backgrounds in our study group. This relationship persisted when we controlled for the typical indicators of socio-economic status, as well as age, parity, and other reported PTD risk factors. Whereas some researchers would view these data as corroboration of the hypothesis that black women possess non-environmental biological traits that increase their risk for PTD, we expect that our proposed measurement of markers of inflammation will enable us to capture subclinical evidence of infection.
Population characteristics and recruitment
The pilot study recruited patients from our Bellevue Hospital clinic patient base. Participants for this study are recruited from the prenatal clinics at Bellevue Hospital Center, and from the high-risk maternal-fetal medicine practice at NYU Medical Center during their first prenatal visit. The ethnic distribution of the clinic obstetric population is 62.0% Hispanic, 12.5% black, 7.5% Asian, 8.0% non-Hispanic white, and 10.0% in other categories, whereas that of the high-risk practice is 90% non-Hispanic white, 5% black, 3% Asian, and 2% Hispanic. The Bellevue patient population includes representation from a number of distinct lowincome urban groups. Many women represent first or second generation immigrants from Central and South America, the Caribbean, Central and Eastern Europe, and South-east Asia. However, we also provide care to women whose backgrounds represent an embedded inner-city public assistance profile. The socio-economic patterns characterising these groups are dramatically different, and therefore, so too are the PTD risk profiles. Conversely, the NYU high-risk practice includes a large proportion of patients with multiple gestation pregnancies, uterine abnormalities, and polyhydramnios. The composite spontaneous PTD rate from both recruitment sites is approximately 10%.
Analysis of data
Three sets of analyses will be performed. The analyses correspond to the three study hypotheses: (1) that accurate and significant risk factors can be identified for PTD; (2) that the identified risk factors can be combined to increase predictive accuracy; 46 and (3) that different mechanisms of PTD can be identified by combining the risk factors. The analyses will assess the accuracy and significance of the risk factors and the statistical models. Analysis 1: Univariate logistic regression will assess the accuracy and significance of each factor.
Analysis 2: Multivariate logistic regression and artificial neural network regression will assess each risk factor and each multivariate model. A sensitivity analysis will be performed to reduce the number of model variables. The multivariate logistic regression models and the artificial neural network regression models will be compared in terms of predictive accuracy.
Analysis 3: Several putative mechanisms of PTD will be assessed. The hypothesised constituent variables of each mechanism will be placed in a model and the predictive accuracy of the model will be determined. If a separable mechanism exists, then a`separable population' should be created by a model containing the variables that give rise to the mechanism. A separable population is defined as a population that possesses a higher predictive accuracy than the population from which it was drawn. Thus, the model that represents the mechanism (i.e. the model is composed of just the variables that are thought to constitute the mechanism) should be more accurate than a model that contains all the PTD variables.
Accuracy
We must be able to compare variable and model accuracy results across different statistical methods, across different data sets for the same statistical method and variables, and within a statistical model for different variables. We must also know if the statistical model is operating as a`naõ Ève Bayes' classifier, i.e. for each case it always predicts the same event (for instance, no PTD), where the predicted event is the one that occurs the most frequently in the training data set. 47 In addition, we need a measure of discriminative accuracy rather than a measure that is the combination of discrimination and calibration. Classifiers that are highly discriminating can always be calibrated, but well-calibrated but poorly discriminating classifiers cannot be improved. 48 Percentage correct is not a useful measure for these analyses because it provides no information regarding whether the model is operating as a naõ Ève Bayes classifier. Sensitivity and specificity are threshold specific, therefore it is difficult to compare the results of different experiments. Positive and negative predictive values are not a useful measure for these analyses because they vary with the prevalence of the test target in the population. Correlation is a combination of discrimination and calibration. Thus, the appropriate measure of accuracy for these analyses is the area under the receiver operating characteristic (ROC) curve, Az. Az is a measure of predictive accuracy. 49 It can be used to assess and compare the adequacy of the covariates and the statistical models. Az can be directly calculated by Somer's D, 50 or it can be approximated by its trapezoidal area. 51 The area under the curve is a non-parametric measure of discrimination. The ROC area is independent of both the prior probability of each outcome and the threshold cut-off for categorisation. Its computation requires only that the prediction method produce an ordinally scaled relative predictive score. In terms of PTD, the ROC area estimates the probability that the prediction method will assign a higher PTD score to the woman who delivered preterm than to the woman who did not. The ROC area varies from zero to one. When the predictions are unrelated to PTD the score is 0.5, indicating chance accuracy. The further the score is from 0.5 the better, on average, the prediction method is at predicting which of the two women will deliver preterm.
Training and testing data sets
The data set will be split randomly into two sub-data sets. One subset, comprising 75% of the data, will be used to train the statistical models. The second subset, comprising 25% of the data, will be used to test the statistical models. Only the test results will be reported. For small data subsets where a crossvalidation based splitting of the data is not possible, model accuracy estimates and standard errors will be calculated by the bootstrap resampling method. 52 
Discussion
This project represents a fundamentally new approach to the prediction of risk for PTD. With our delineation of the four primary pathways resulting in PTD, we build upon recent developments in the biochemistry of parturition by offering a unifying theoretical framework for understanding the role of many biochemical, biophysical, epidemiological, and clinical markers of PTD. In addition, we add consideration of novel biochemical markers (e.g. FasL, tissue factor). Finally, we apply the most powerful new modelling technique available for understanding multifactorial processes through our use of an artificial neural network.
Since there is abundant evidence that PTD occurs through the initiation of a number of pathogenic processes, this project represents a serious attempt to segregate these processes into constituent pathways. Through identification of the primary pathogenic process operating in any given case, our approach carries the promise that targeted therapy can be applied to those individuals identified as at highest risk for a PTD resulting from a given pathogenic process. It is our contention that by this mode of intervention significant progress can be made in reducing the rate of PTD.
